Literature DB >> 7351110

Kinetic discrimination of three sulfamethazine acetylation phenotypes.

D J Chapron, P A Kramer, S A Mercik.   

Abstract

The relationship between sulfamethazine disposition kinetics and acetylator phenotype was studied in 19 healthy subjects. Various kinetic parameters for sulfamethazine and its N4-acetylated metabolite were determined after a dose of a rapidly absorbed oral solution. When plotted on a frequency distribution histogram, the results exhibited a well-defined trimodal pattern for acetylation clearance values and overall elimination or metabolic rate constants. These data were consistent with the well-recognized acetylation polymorphism for sulfamethazine, except that they clearly subdivided the previously acknowledged "fast" acetylator mode into intermediate and rapid acetylator groups. The apparent distribution volume and renal clearance for sulfamethazine and acetylsulfamethazine did not differ significantly among the 3 phenotypes. Of special interest was the observation that rapid acetylators initially produce much greater amounts of acetyl metabolite than intermediate acetylators. The potential clinical implications of identifying rapid and intermediate acetylators are discussed in view of evidence showing that acetyl metabolites may be pharmacologically active or function as intermediates in toxic metabolic pathways.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7351110     DOI: 10.1038/clpt.1980.16

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  17 in total

1.  Codominant expression of N-acetylation and O-acetylation activities catalyzed by N-acetyltransferase 2 in human hepatocytes.

Authors:  Mark A Doll; Yu Zang; Timothy Moeller; David W Hein
Journal:  J Pharmacol Exp Ther       Date:  2010-04-29       Impact factor: 4.030

2.  Effect of iron deficiency anaemia and its treatment on sulphadimidine absorption.

Authors:  N A Kshirsagar; Y S Saraf; M R Takle; M V Joshi; R S Satoskar; B C Mehta; V N Acharya
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 3.  Assessment of the drug metabolism capacity of the liver.

Authors:  B K Park
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

4.  Acetylator phenotype and serum levels of sulfapyridine in patients with inflammatory bowel disease.

Authors:  M E Sharp; S M Wallace; K W Hindmarsh; M A Brown
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

5.  Endralazine - a new hydralazine-like antihypertensive with high systemic bioavailability.

Authors:  P A Reece; I Cozamanis; R Zacest
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 6.  Ethnic differences in drug metabolism.

Authors:  W Kalow
Journal:  Clin Pharmacokinet       Date:  1982 Sep-Oct       Impact factor: 6.447

7.  Distribution of acetylator phenotype in relation to age and sex in Swedish patients. A retrospective study.

Authors:  O Paulsen; L G Nilsson
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  A simple pharmacokinetic method for separating the three acetylation phenotypes: a preliminary report.

Authors:  E J Lee; L K Lee
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

Review 9.  Drug metabolites in renal failure: pharmacokinetic and clinical implications.

Authors:  R K Verbeeck; R A Branch; G R Wilkinson
Journal:  Clin Pharmacokinet       Date:  1981 Sep-Oct       Impact factor: 6.447

10.  A simple test for acetylator phenotype using caffeine.

Authors:  D M Grant; B K Tang; W Kalow
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.